Around Fairweather Image
Home Page > Publications & Presentations

 

Publications & presentations

 . 2013 . 2012  . 2011

 

 

 

2013

 

Publications

 

  1. Simmons R, Semeneko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. AIDS Behav 2013 (in press).
  2. Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD, for EuroSIDA in EuroCoord. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients. PLoS One 2013 (in press).
  3. Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O and Meyer L on behalf of the CASCADE Collaboration in Eurocoord. Natural History of HIV control since seroconversion Experience from the CASCADE collaboration. AIDS 2013 (in press).
  4. Pantazis N, Kenward MG, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Performance of parametric survival models under non-random interval censoring: a simulation study. Computational Statistics and Data Analysis 2013 (in press).
  5. Rosińska M, Marzec-Boguslawska A, Janiec J, Smolen-Dzirba J, Wasik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K for the CASCADE Collaboration in EuroCoord. High percentage of recent HIV infection among HIV-positive individuals newly-diagnosed at voluntary counselling and testing sites in Poland in 2006. AIDS Res Hum Retroviruses 2013;29:805-13. [PubMed]
  6. Ryom L, Kirk O, Lundgren J, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell J, Mocroft A; EuroSIDA in EuroCoord. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med 2013 Apr 16.[Epub ahead of print]
  7. Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh J, Mocroft A; EuroSIDA in EuroCoord. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med 2013 Mar 27.[Epub ahead of print]
  8. Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher H, Kücherer C, Zangerle R, Bakken Kran AM, Porter K, on behalf of the CASCADE collaboration in EuroCoord. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline and viral load set point in European seroconverter cohorts. CID 2013;56:888-97. [PubMed]
  9. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Predictors of CD4 cell counts of HIV-1-infected persons after virologic failure to all three original antiretroviral drug classes. JID 2013;207:759-67. [PubMed]
  10. Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C. On Behalf of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS Behav 2013 Jan;17:193-202. [PubMed]
  11. Mocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren JD; for EuroSIDA in EuroCoord. CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS 2013;27:907-918.[abstract]
  12. Søgaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, Servitskiy S, Domingo P, Reiss P, Mocroft A, Kirk O. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. J Infect 2013;66:439-46. [Article]

 

 

Conference presentations

 

  1. Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Duiculescu D, Zilmer K, Clotet B, Lundgren JD, Paredes R for EuroSIDA in EuroCOORD. Detection of Non-R5 HIV-1 by Ultrasensitive Genotypic Testing Is Associated with CD4+ Count Decreases Also After the Initiation of ART. 11th European Meeting on HIV & Hepatitis, 20-22 March 2013, Rome, Italy.[poster]
  2. Olson A, Touloumi G, Geskus R, Meyer L, Prins M, Chêne G, De Luca A, Costagliola D, and Porter K for CASCADE Collaboration in EuroCoord. Mean asymptomatic viral load, steady state viral load and CD4 cell count following acute infection as predictors of HIV disease progression.20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  3. Wittkop L on behalf of the EuroCoord-CHAIN subtype project team. Effect of HIV-1 subtypes on virological and immunological response to initial combination antiretroviral therapy (cART) – a European Multicohort Study. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  4. Mocroft A on behalf of the Opportunistic Infections project group of COHERE in EuroCoord. The incidence and risk of AIDS-defining illnesses (ADIs) at current CD4 counts of 500/mm3 or higher. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [Abstract]
  5. Grint D, Peters L, Rockstroh J, Lundgren JD, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Mocroft A. Increased Risk Of Antiretriviral Drug Discontuniation among Patienst with High Hyaluronic Acid, a Marker of Liver Fibrosis. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [abstract]
  6. Mocroft A, Ryom L, Reiss P, Ledergerber B, Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren JD and Kirk O for EuroSIDA in EuroCoord. A comparison of estimated glomerular reates (eGFRs) using Cockcroft-Gault (CG) and the CKD-EPI estimating equations. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [abstract]
  7. Bailey H, Townsend CL, Cortina Borja M, Thorne C for the European Collaborative Study in EuroCoord. Trends and factors associated with virological failure among women conceiving on cART in Western Europe.  20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, US. [abstract]

 

 

 

2012

 

Publications

 

 

  1. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS 2012. [Epub ahead of print]
  2. Van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M on behalf of CASCADE collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality following HIV seroconversion before and after 1997. Gastroenterology 2013;144:751-760. [PubMed]
  3. Huang X, Lodi S , Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li A,  Xu X, Wu H and Johnson A, on behalf of the CASCADE collaboration in EuroCoord. Rate of CD4 decline and HIV-RNA change following HIV Seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. JAIDS 2012. [Epub ahead of print]
  4. Lodi S, del Amo J, D’Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E, and theCASCADE collaboration in EuroCoord.Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries. Thorax 2012;68:207-13. [PubMed]
  5. Smoleń-Dzirba J, Rosińska M, Kruszyński P, Bratosiewicz-Wasik J, Janiec J, Beniowski M, Bociaga-Jasik M, Jablonowska E, Szetela B, Porter K, Wasik T, and the CASCADE collaboration in EuroCoord. Molecular epidemiology of recent HIV-1 infections in southern Poland. J Med Virol 2012;84:1857-68. [PubMed]
  6. Podlekareva DN, Reekie J,  Mocroft A, Losso M, Rakhmanova A, Bakowska E, Karpov IA, Lazarus J, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord. Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infect Dis 2012;12:229. [PubMed]
  7. Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; for EuroSIDA in EuroCoord. HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012;26:1917-1926. [PubMed]
  8. Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; the EuroSIDA Study in EuroCOORD. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther 2012;17:1291-300 [PubMed] 
  9. Hepatitis working group for COHERE in EuroCoord. Effect of hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients. Antivir Ther 2012;17:1541-1550. [PubMed] 
  10. Zugna D, Geskus RB, de Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M, Babiker A and Porter K for the CASCADE Collaboration in EuroCoord. Differences in time to virological failure, treatment change and interruption, between persons treated within 12 months of HIV seroconversion and in chronic infection. Antivir Ther 2012;17:1039-1048. [PubMed]
  11. Lodi S, Meyer L, Kelleher A, Rosińska M, Ghosn J, Sannes M, Porter K for the CASCADE Collaboration in EuroCoord. Immuno-virological control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252-5. [PubMed]
  12. Bakoyannis G, Touloumi G. Practical methods for competing risks data: A review. Stat Methods Med Res 2012; 21: 257-72.  [PubMed]
  13. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O,  Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA Study. PLoS One 2012;7:e41673. [Article]
  14. de Wolf F, Sabin C, Kirk O, Thorne C, Chene G, Porter K for EuroCoord. Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience. Clin Invest 2012; 2: 255-264. [Article]
  15. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. All-cause mortality in treated HIV-infected adults with CD4 ≥500 /mm3 compared to the general population: evidence from a large European observational cohort collaboration. Int. J. Epidemiol. 2012; 41: 433-445. [PubMed]
  16. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G on behalf of CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One. 2012; 7: e32369. [Article]
  17. Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C; European Paediatric HIV and Lipodystrophy Study Group in EuroCoord. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr. 2012; 59: 314-24. [PubMed]
  18. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Med. 2012; 9: e1001194. [Article]
  19. Nakagawa F for the PLATO II group for COHERE in EuroCoord. Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012; 59: 294-9. [PubMed]
  20. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. 2012; 12: 119-27. [PubMed]
  21. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, Monforte A, Phillips A, Lundgren J and Kirk O for the EuroSIDA study group. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012; 26: 315-323. [PubMed]
  22. Cozzi-Lepri A, Paredes R, Phillips AN, Clotet B, Kjær J, Von Wyl V, Kronborg G, Castagna A, Bogner JR and Lundgren JD for EuroSIDA in EuroCoord. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI.HIV Med. 2012; 13: 62-72. [PubMed]
  23. Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, García de Olalla P, Porter K, Del Amo J; CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis. 2012; 54: 111-8. [PubMed]
  24. Thorne C, Semenenko I, Malyuta R; for the Ukraine European Collaborative Study Group in EuroCoord. Prevention of mother-to-child transmission of HIV among pregnant women using injecting drugs in Ukraine, 2000-2010. Addiction 2012; 107: 118-28. [Pubmed]

 

 

Conference presentations

 

  1. Bastiaans DET et al on behalf of the PENTA 18 KONCERT Study Group. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. 6th Netherlands Conference on HIV Pathogenesis, Prevention and Treatment, 27 November 2012, Amsterdam, Netherlands.
  2. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jetovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A for EuroSIDA in EuroCoord. Temporal Changes and Regional Differences in Treatment Uptake of Hepatitis C Therapy in EuroSIDA. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  3. Mocroft M, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren J et al. for theEuroSIDA study in EuroCoord. CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  4. Rockstroh JK, Grint D, Boesecke C, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Kirk O, Mocroft A and Peters L for EuroSIDA in EuroCoord. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  5. Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM and Mocroft A on behalf of EuroSIDA in EuroCoord. Advanced Chronic Kidney Disease, End-Stage Renal Disease and Renal Death in HIV-Positive Individuals in Europe. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  6. Zoufaly A, Cozzi-Lepri A, Kirk O, Lundgren JD, Reiss P, Jetovic D, Machala L, Zangerle R, Mocroft A, van Lunzen J on behalf of EuroSIDA in EuroCoord. Immuno-virological discordance (ID) is associated with a higher frequency of fatal and non-fatal AIDS and non-AIDS. 11th International Congress on Drug Therapy in HIV infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  7. Aebi-Popp K, Mulcahy F, Glass T, Rudin C, Martinez de Tejada B, Bertisch B, Grawe C, Rickenbach M, Scheibner K, Hösli I and Thorne C  for the European Collaborative Study in EuroCoord and the Swiss Mother & Child HIV Cohort Study. Pregnant women with HIV in Europe: How many achieve the aim of undetectable viral load at term and are able to deliver vaginally? 11th International Congress on Drug Therapy in HIV Infection, 11-15 November 2012, Glasgow, UK. [Abstract]
  8. Janiec J, Rosińska M, Smoleń-Dzirba J, Wąsik T, Beniowski M, Bociąga-Jasik M, Kalinowska-Nowak A, Jabłonowska E, Szetela B, Zalewska M, Porter K and the CASCADE collaboration in EuroCoord. What shapes the current HIV epidemic in southern Poland? Poster presentation 2012 European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE), 24-26 October 2012, Edinburgh, Scotland, UK.
  9. Pantazis N, Kenward M, Touloumi G on behalf of CASCADE Collaboration in EuroCoord. Performance of parametric survival models under non-random interval censoring: a simulation study. 33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen, Norway. Published in the 33rd Conference of the International Society for Clinical Biostatistics programme and abstract book, abstract P22.26, p.130. [Abstract]
  10. Bakoyannis G. Late entry bias in cohort studies with competing endpoints. 33rd Conference of the International Society for Clinical Biostatistics, 19-23 August 2012, Bergen, Norway. Published in the 33rd Conference of the International Society for Clinical Biostatistics programme and abstract book, abstract C26.4, p.66. [Abstract]
  11. Thorne C, Malyuta R, Semenenko I, Azhischeva E, Baryshnikova Y, Bashkatova N, Glutshenko E, Kaleeva N, Raus I, Soloha S, Ene L, Giaquinto C, Ukraine Paediatric HIV Cohort Study in EuroCoord. HIV disease progression markers and treatment of HIV-positive children in Ukraine. 19th International AIDS Conference, July 22-27 2012, Washington DC, USA. [Abstract]
  12. Smith R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Malyuta R, Porter K on behalf of CASCADE Collaboration in EuroCoord. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. 19th International AIDS Conference, 22-27 July 2012, Washington DC, US. [Abstract]
  13. Lundgren J on behalf of the COHERE Late Presenters working group. Characteristics of individuals presenting late for care across Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). 19th International AIDS Conference, 22-27 July 2012, Washington DC, US. [Abstract]
  14. Bailey H, Malyuta R, Semenenko I, Townsend CL, Cortina Borja M and Thorne C for the Ukraine European Collaborative Study in EuroCoord. Receipt of cART among childbearing women in Ukraine: implications for vertical and horizontal transmission. Poster accepted for 4th International Workshop on HIV Pediatrics, 20-21 July 2012, Washington DC, USA.  
  15. Bastiaans D, Forcat S, Lyall H, Cressey T, Chalermpantmetagul S, Saïdi Y, Noguera Fortuny C, Compagnucci A, Bleier J, Giaquinto C, Colbers A, Burger D on behalf of PENTA KONCERT Study Group. Pharmacokinetics of 100/25 mg lopinavir/ritonavir tablets in children when dosed twice daily according to FDA weight bands. 4th International Workshop on HIV Pediatrics, 20-21 July 2012 Washington DC, US.
  16. Chiappini E, Ene L, Galli L, Giaquinto C, Goetghebuer T, Noguera AJ, Ramos JT, Rudin C, Tookey P, Thorne C (European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord). Use of mono and combined neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in high risk situations in Europe.  4th International Workshop on HIV Pediatrics, Washington DC, USA, 20-21 July 2012.
  17. Van der Helm J on behalf of the CASCADE collaboration. Effect of hepatitis C coinfection on cause-specific mortality following HIV seroconversion in the pre-cART and cART eras. 47th annual meeting of the European Association for the Study of Liver (EASL), 18-22 April 2012,Barcelona, Spain.[Abstract]
  18. Judd A, Duong T, Ene L, Galli L, Goetghebuer T, Noguera-Julian A, Ramos J, Tookey P, Naver L, Thorne C and Giaquinto C on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord. Safety of fosamprenavir and darunavir in HIV-1 infected children in the European Union: ongoing post-marketing surveillance studies.  30th Annual meeting of the European Society for Paediatric Infectious Diseases, 8-12 May 2012, Thessaloniki, Greece. [Abstract]
  19. Olson A, Meyer L, Prins M, Thiebaut R, Guiguet M, Chaix M-L, Amornkul P, Babiker A and Porter K for CASCADE Collaboration in EuroCoord. Proportion of HIV elite controllers and loss of elite status according to two commonly used definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Abstract]
  20. Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Porter K for CASCADE Collaboration in EuroCoord. Identification of severe primary HIV infection through clinical, immunological and virological definitions. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US. [Abstract]
  21. Ramos J, Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, Barclay L, Ory S, Giaquinto C, Gibb D. on behalf of the PENTA Steering Committee. Neurocognitive and Quality of Life Outcomes in Children after Planned Treatment Interruptions: the randomized PENTA 11 trial. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, US.[Abstract]

 

 

 

 

2011

 

Publications

 

  1. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord (Judd A, Penazzato M, Townsend C, Duong T, Castro H, Goetghebuer T, Warszawski J, Galli L, Chiappini E, de Martino M, Ene L, Giaquinto C, Königs C, LeChenadec J, Lyall H, Noguera Julian A, Ramos JT, Rojo-Conejo P, Rudin C, Thorne C, Tookey P, Tudor-Williams G, Gibb DM). Early antiretroviral therapy in HIV-1 infected infants in Europe, 1996-2008: treatment response and duration of first line regimens. AIDS 2011; 25: 2279-2287. [PubMed]
  2. Reekie J, Gatell J, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska J, Mocroft A, for the EuroSIDA in EuroCoord. Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. AIDS. 2011; 25: 2259-68. [PubMed]
  3. Cozzi-Lepri A, Prosperi MCF, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies. Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. PLoS One. 2011; 6: e25665.[Article]
  4. Soriano V, Grint D, Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011; 25: 1987-92. [PubMed]
  5. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, del Amo J, Johnson A M, Babiker A, Porter K on behalf of the CASCADE Collaboration in EuroCoord. Time from HIV seroconversion to reaching CD4 thresholds <200, <350 and <500 cells/mm3; assessment of need following changes in treatment guidelines. Clin Infec Dis 2011; 53: 817-825. [PubMed]
  6. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171: 1560-9. [Pubmed]
  7. Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J, the EuroSIDA study group. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J Infect Dis. 2011; 204: 741-52. [PubMed]
  8. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Tuberculosis among HIV-postive patients across Europe: changes over time and risk factors. AIDS 2011; 25: 1505-1513. [PubMed]
  9. Jaffe H, De Stavola B, Carpenter L, Porter K and Cox D. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011; 25: 1395-1403. [PubMed] 
  10. European Collaborative Study in EuroCoord, Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther. 2011; 16: 895-903. [PubMed]
  11. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A for the EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011; 25: 1305-1315. [PubMed]
  12. Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. Blood 2011; 117: 6100-8. [PubMed]
  13. Fox ZV, Cozzi-Lepri A, d'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD for EuroSIDA. Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA. Antivir Ther 2011; 16: 781-5. [PubMed]
  14. Van der Helm J, Prins M, Del Amo J, Bucher H, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R. The hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. AIDS 2011; 25: 1083-1091. [PubMed]
  15. Mussini C,  Cossarizza A, Sabin C,  Babiker A, De Luca A, Bucher H, Fisher M, Rezza G, Porter K, Dorrucci M. Decline of CD4+ T cell count before start of therapy and immunological response to treatment in antiretroviral-naïve individuals. AIDS 2011; 25: 1041-104. [PubMed]
  16. The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet 2011; 377: 1580-1587. [PubMed]
  17. Wittkop L, Günthard H, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, for the EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-371. [PubMed] 
  18. The PENPACT-1 (PENTA 9 / PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, Melvin A, Mofenson L, Saidi Y, Smith ME, Tudor-Williams G, Walker AS. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infect Dis. 2011; 11: 273-283. [PubMed]
  19. Bannister W, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A,  Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; the EuroSIDA study group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011; 66: 901-11. [PubMed]
  20. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; for the EuroSIDA study group. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. HIV Clin Trials 2011; 12: 109-17. [PubMed]

 


Conference presentations

 

  1. Soriano V on behalf of the EuroSIDA study. Hepatitis delta in HIV-infected individuals in Europe. 13th European AIDS Conference/EACS, Belgrade, October 2011. 
  2. Søgaard on behalf of the EuroSIDA study. The incidence of serious non-AIDS defining infections in the EuroSIDA cohort. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  3. Peters L on behalf of the EuroSIDA study. Chronic hepatitis C (HCV) infection and chronic kidney disease (CKD) in HIV-infected patients in the EuroSIDA study. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  4. Grint D, A Phillips on behalf of the EuroSIDA study.  Predictors of hepatitis C viremia in co-infected individuals. 13th European AIDS Conference/EACS, Belgrade, October 2011.
  5. Thorne C, Vigano A, Goetghebuer T, Alam N for the European Paediatric HIV and Lipodystrophy Study in EuroCoord. Components of metabolic syndrome in young adults with life-long HIV. 17-20 July 2011 IAS, Rome, Italy [Abstract]
  6. Podlekareva DN, Grint D, Panteleev A, Rakhmanova A, Miller R, Bruyand M, Furrer H, Post F, Zeltina I, Skrahin A, Miro JM, Obel N, Girardi E, Losso MH, Toibaro J, Caylá J, Lundgren JD, Kirk O, HIV/TB Collaboration Study Group. Mortality Rate, TB Recurrence and Causes of Death in HIV/TB Coinfected Patients: Results from the HIV/TB Collaborative Study. 13th European AIDS Conference/EACS, Belgrade, October 2011. [Presentation]
  7. Malyuta R, Semenenko I, Azhischeva H, Peters H, Thorne C for the Ukraine Paediatric HIV Cohort Study in EuroCoord. Children living with HIV in Ukraine: establishing a new paediatric cohort study. 3rd International Workshop on HIV Pediatrics, 17-20 July 2011 IAS, Rome, Italy [Abstract]
  8. Lodi S, d’Arminio Monforte A, del Amo J, Abgrall S, Sabin C, Porter K, Girardi E. Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011.[Abstract]
  9. Huang X, Lodi S, Fox Z, Phillips A, Johnson A, Porter K, Xu X and Wu H on behalf of the Beijin PRIMO cohort study and the CASCADE collaboration. Patterns of decrease in CD4 cell count after seroconversion: Comparison between Beijing PRIMO cohort and CASCADE seroconverter cohorts. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Abstract]
  10. Judd A, Ene L, Goetghebuer T, Noguera A, Ramos JT, Thorne C, Duong T, Giaquinto C on behalf of the European Pregnancy and Paediatric HIV Cohort Collaboration in EuroCoord. Use and safety of fosamprenavir in HIV-infected children in the European Union: an ongoing post-marketing surveillance study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Abstract]
  11. Compagnucci A on behalf of the PENTA Steering Committee. Long term consequences of planned treatment interruptions in HIV infected children: Results from the TICCH (Treatment Interruption in Children with Chronic HIV-Infection) /PENTA 11 trial. 3rd International Workshop on HIV Pediatrics, 17-20 July 2011 IAS, Rome, Italy.Published in Reviews in Antiviral Therapy & Infectious Diseases 2011; 8: Abstract no. O_10, p.12. [Abstract]
  12. Heiner C. Bucher on behalf of the OI working group of COHERE. Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected patients with sustained viral response to cART. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, July 2011. [Abstract]
  13. Van der Helm J, Prins M, del Amo J, Bucher H C, Chêne G, Dorrucci M, Gill M J, Hamouda O, Sannes M, Porter K, Geskus R B, on behalf of the CASCADE collaboration. The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007. International Liver Congress 30 March- 3 April 2011 EASL, Berlin, Germany [Abstract]
  14. Touloumi G, Pantazis N, Chaix M L, Meyer L, Thiebaut R, Masquelier B, Kücherer C, d’Arminio Monforte A, Lodi S, Porter K, and CASCADE. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE Collaboration. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011.
  15. Smit C, d'Arminio A, de Wolf F, Puoti M, Dabis F on behalf of the HCV working group of COHERE. HCV Treatment and CD4 Cell Count Decline in HIV/HCV Co-infected Patients: European Cohort Collaboration. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Abstract]
  16. Kowalska JD, Mocroft A, Reekie J, Phillips A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Lundgren JD and Kirk O for the EuroSIDA study group. Risk of Cause-specific Deaths over Calendar Time and according to Cumulative Exposure to Combination Antiretroviral Therapy (cART). 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Abstract]
  17. Cozzi-Lepri A, Paredes R, Phillips A, Kjær J, Lazzarin A, van Lunzen J, Karlsson A, Johnson M, and Lundgren J for the EuroSIDA study group. Predictors of Virologic Response to Etravirine-based cART Regimens in a Large European Cohort of HIV-infected Patients. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 2011. [Abstract]

 

| Home Page | Site Map | Search | FAQ | Feedback | List Access Keys |